Table 2.

Relative risk of AML by age following exposure to alkylator chemotherapy for the treatment of myeloma and NHL

Site	N	15–49 years RR (95% CI)	P-value	N	50–64 years RR (95% CI)	P-value	N	65 years plus RR (95% CI)	P-value
Myeloma	2,324	3.16 (0.35–28.22)	0.392	8,906	9.33 (1.27–68.53)	0.004	22,204	6.0000 (2.70–13.35)	<0.001
NHL	21,976	10.33 (3.16–33.80)	<0.001	26,543	4.23 (2.31–7.74)	<0.001	53,869	2.1154 (1.33–3.37)	0.001

RR relative risk, NHL non-hodgkin lymphoma, CI, confidence interval, N number of patients